233 related articles for article (PubMed ID: 17392724)
1. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
Bouligand J; Le Maitre A; Valteau-Couanet D; Grill J; Drouard-Troalen L; Paci A; Hartmann O; Benhamou E; Vassal G
Clin Pharmacol Ther; 2007 Oct; 82(4):402-9. PubMed ID: 17392724
[TBL] [Abstract][Full Text] [Related]
2. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen.
Cacchione A; LeMaitre A; Couanet DV; Benhamou E; Amoroso L; Simonnard N; Hartmann O
Bone Marrow Transplant; 2008 Oct; 42(7):449-54. PubMed ID: 18587430
[TBL] [Abstract][Full Text] [Related]
5. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.
Méresse V; Hartmann O; Vassal G; Benhamou E; Valteau-Couanet D; Brugieres L; Lemerle J
Bone Marrow Transplant; 1992 Aug; 10(2):135-41. PubMed ID: 1525602
[TBL] [Abstract][Full Text] [Related]
7. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
8. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.
Vassal G; Koscielny S; Challine D; Valteau-Couanet D; Boland I; Deroussent A; Lemerle J; Gouyette A; Hartmann O
Cancer Chemother Pharmacol; 1996; 37(3):247-53. PubMed ID: 8529285
[TBL] [Abstract][Full Text] [Related]
9. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the effects of preconditioning regimens on hepatic veno-occlusive disease in mice after hematopoietic stem cell transplantation.
Qiao J; Fu J; Fang T; Huang Y; Mi H; Yang N; Chen C; Xu K; Zeng L
Exp Mol Pathol; 2015 Feb; 98(1):73-8. PubMed ID: 25533545
[TBL] [Abstract][Full Text] [Related]
11. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
[TBL] [Abstract][Full Text] [Related]
12. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.
McCune JS; Gooley T; Gibbs JP; Sanders JE; Petersdorf EW; Appelbaum FR; Anasetti C; Risler L; Sultan D; Slattery JT
Bone Marrow Transplant; 2002 Aug; 30(3):167-73. PubMed ID: 12189535
[TBL] [Abstract][Full Text] [Related]
13. Chronopharmacology of high-dose busulfan in children.
Vassal G; Challine D; Koscielny S; Hartmann O; Deroussent A; Boland I; Valteau-Couanet D; Lemerle J; Lévi F; Gouyette A
Cancer Res; 1993 Apr; 53(7):1534-7. PubMed ID: 8453619
[TBL] [Abstract][Full Text] [Related]
14. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome.
Lee SH; Yoo KH; Sung KW; Koo HH; Kwon YJ; Kwon MM; Park HJ; Park BK; Kim YY; Park JA; Im HJ; Seo JJ; Kang HJ; Shin HY; Ahn HS
Bone Marrow Transplant; 2010 Aug; 45(8):1287-93. PubMed ID: 20010866
[TBL] [Abstract][Full Text] [Related]
15. High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy.
Valteau-Couanet D; Fillipini B; Benhamou E; Grill J; Kalifa C; Couanet D; Habrand JL; Hartmann O
Bone Marrow Transplant; 2005 Dec; 36(11):939-45. PubMed ID: 16184181
[TBL] [Abstract][Full Text] [Related]
16. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
17. High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma.
Hwang DY; Kim SJ; Cheong JW; Kim Y; Jang JE; Lee JY; Min YH; Yang WI; Kim JS
Leuk Lymphoma; 2016; 57(1):51-7. PubMed ID: 25899401
[TBL] [Abstract][Full Text] [Related]
18. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
Lee JL; Gooley T; Bensinger W; Schiffman K; McDonald GB
Biol Blood Marrow Transplant; 1999; 5(5):306-15. PubMed ID: 10534061
[TBL] [Abstract][Full Text] [Related]
19. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma.
Horn B; Reiss U; Matthay K; McMillan A; Cowan M
Bone Marrow Transplant; 2002 Mar; 29(5):409-15. PubMed ID: 11919731
[TBL] [Abstract][Full Text] [Related]
20. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.
Bartelink IH; Bredius RG; Belitser SV; Suttorp MM; Bierings M; Knibbe CA; Egeler M; Lankester AC; Egberts AC; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2009 Feb; 15(2):231-41. PubMed ID: 19167683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
